Authors

• Francesca Bovis (ORCID: https://orcid.org/0000-0002-3823-4000)
• Carmen Tur (ORCID: https://orcid.org/0000-0003-1849-3184)
• Irene Schiavetti (ORCID: https://orcid.org/0000-0002-5460-2977)
• Alessandro Cagol (ORCID: https://orcid.org/0000-0002-7703-0553)
• Ludwig Kappos (ORCID: https://orcid.org/0000-0003-4175-5509)
• Maria Pia Sormani (ORCID: https://orcid.org/0000-0001-6892-104X)
• Douglas Lorne Arnold (ORCID: https://orcid.org/0000-0003-4266-0106)
• Noemi Montobbio (ORCID: https://orcid.org/0000-0003-0302-393X)
• Marta Ponzano (ORCID: https://orcid.org/0000-0003-4091-4686)
• Cristina Granziera (ORCID: https://orcid.org/0000-0002-4917-8761)
• Alessio Signori
• Luca Carmisciano

Institutions

• University of Pisa (IT)
• Universitat Autònoma de Barcelona (ES)
• Montreal Neurological Institute and Hospital (CA)
• University Hospital of Basel (CH)
• Hospital Base (CL)
• Ospedale Policlinico San Martino (IT)
• University of Genoa (IT)

Publication Details

Journal

EBioMedicine

Published

2025-06-18

DOI

https://doi.org/10.1016/j.ebiom.2025.105802

Citations

2

Primary Topic

Multiple Sclerosis Research Studies

Type

article

Field-Weighted Citation Impact

2.94

Funders

• Bristol-Myers Squibb
• Eli Lilly and Company
• Sanofi
• Biogen
• European Committee for Treatment and Research in Multiple Sclerosis
• Kiniksa Pharmaceuticals
• International Progressive MS Alliance
• Celltrion
• Galápagos
• Multiple Sclerosis Society of Canada
• Multiple Sclerosis Society
• European Commission
• Shionogi
• Innosuisse - Schweizerische Agentur für Innovationsförderung
• Idorsia Pharmaceuticals
• Genentech
• EMD Serono